Hepatitis C
1,002
25
33
716
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
260 trials with published results (26%)
Research Maturity
716 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.5%
75 terminated out of 1002 trials
90.5%
+3.9% vs benchmark
23%
227 trials in Phase 3/4
36%
260 of 716 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 716 completed trials
Clinical Trials (1002)
Evaluation of Patients With Liver Disease
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
The Australian HCV Point-of-Care Testing Program
The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)
HCV Self-testing in Pakistan
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
HCV Self-testing in Georgia
HCV Self-testing in Malaysia
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
Buprenorphine Integration Research and Community Health
Tele-Harm Reduction
Strengthening, Guidance, Health, Empowerment
Identification of Hepatitis C Virus (HCV) Specific T Cells
Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Reaching mEthadone Users Attending Community pHarmacies With HCV